Supporting this notion, Cd63 is considered a negative driver of advanced stages of melanoma, as it inhibits epithelial-mesenchymal transition (EMT), and thus invasive migratory behavior (Radford et al., 1997; Jang and Lee, 2003; Lupia et al., 2014). Here, CD63 is linked to melanoma.